LIVN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

353.50M

+9.85%

0.810

+0.05%

339.13M

+7.02%

0.891

+1.3%

374.77M

+6.32%

1.129

+7.48%

Estimates Revision

The market is revising Upward the revenue expectations for LivaNova PLC (LIVN) for FY2025, with the revenue forecasts being adjusted by 0.79% over the past three months. During the same period, the stock price has changed by 14.80%.

Revenue Estimates for FY2025

Revise Upward

+0.79%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.75%

In Past 3 Month

Stock Price

Go Up

+14.80%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 65.83 USD with a low forecast of 55.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

Current: 63.060

Low

55.00

Averages

65.83

High

85.00

Current: 63.060

Low

55.00

Averages

65.83

High

85.00

Baird

Outperform

maintain

$70 -> $75

2025-12-16

New

Reason

Baird

Price Target

$70 -> $75

2025-12-16

New

maintain

Outperform

Reason

Baird raised the firm's price target on LivaNova to $75 from $70 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Baird

Outperform

maintain

$63 -> $70

2025-11-13

Reason

Baird

Price Target

$63 -> $70

2025-11-13

maintain

Outperform

Reason

Baird raised the firm's price target on LivaNova to $70 from $63 and keeps an Outperform rating on the shares. The firm updated its model following its Investor Day which outlined its portfolio transformation to accelerate growth to 2028 and beyond.

Mizuho

Outperform

upgrade

$65 -> $70

2025-11-13

Reason

Mizuho

Price Target

$65 -> $70

2025-11-13

upgrade

Outperform

Reason

Mizuho raised the firm's price target on LivaNova to $70 from $65 and keeps an Outperform rating on the shares following the investor day. The firm upped estimates following the event.

Baird

David Rescott

Outperform

maintain

$61 -> $63

2025-11-06

Reason

Baird

David Rescott

Price Target

$61 -> $63

2025-11-06

maintain

Outperform

Reason

Baird analyst David Rescott raised the firm's price target on LivaNova to $63 from $61 and keeps an Outperform rating on the shares. The firm updated its model following results showing another quarter of double digit growth which is laying a solid foundation heading into its analyst day.

Goldman Sachs

Buy

Neutral

downgrade

$56 -> $55

2025-10-01

Reason

Goldman Sachs

Price Target

$56 -> $55

2025-10-01

downgrade

Buy

Neutral

Reason

Goldman Sachs downgraded LivaNova to Neutral from Buy with a price target of $55, down from $56. The firm believes that as the Essenz product cycle passes the halfway point, LivaNova's decelerating sales growth and slowing rate of margin expansion are likely to limit the potential for multiple expansion. Consensus estimates now more appropriately capture the company's forward outlook, the analyst tells investors in a research note.

Barclays

Matt Miksic

Equal Weight

maintain

$55 -> $58

2025-08-21

Reason

Barclays

Matt Miksic

Price Target

$55 -> $58

2025-08-21

maintain

Equal Weight

Reason

Barclays analyst Matt Miksic raised the firm's price target on LivaNova to $58 from $55 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect management's commentary and updated 2025 outlook.

Valuation Metrics

The current forward P/E ratio for LivaNova PLC (LIVN.O) is 16.00, compared to its 5-year average forward P/E of 22.45. For a more detailed relative valuation and DCF analysis to assess LivaNova PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

22.45

Current PE

16.00

Overvalued PE

32.54

Undervalued PE

12.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

15.57

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

21.45

Undervalued EV/EBITDA

9.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.80

Current PS

0.00

Overvalued PS

3.66

Undervalued PS

1.93

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LIVN News & Events

Events Timeline

No data

News

3.5

12-03Newsfilter

LivaNova Presents Significant Seizure Reduction with VNS Therapy at AES Annual Meeting

5.0

12-02Newsfilter

LivaNova Appoints New Global Head of Commercialization for OSA to Drive Market Growth

7.0

11-24Newsfilter

LivaNova's VNS Therapy Reimbursement Increases by 48% Under Medicare

People Also Watch

Frequently Asked Questions

What is LivaNova PLC (LIVN) stock price today?

The current price of LIVN is 63.06 USD — it has increased 0.49 % in the last trading day.

What is LivaNova PLC (LIVN)'s business?

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.

What is the price predicton of LIVN Stock?

What is LivaNova PLC (LIVN)'s revenue for the last quarter?

LivaNova PLC revenue for the last quarter amounts to 357.75M USD, increased 12.46 % YoY.

What is LivaNova PLC (LIVN)'s earnings per share (EPS) for the last quarter?

LivaNova PLC. EPS for the last quarter amounts to 0.49 USD, decreased -18.33 % YoY.

What changes have occurred in the market's expectations for LivaNova PLC (LIVN)'s fundamentals?

How many employees does LivaNova PLC (LIVN). have?

LivaNova PLC (LIVN) has 2900 emplpoyees as of December 16 2025.

What is LivaNova PLC (LIVN) market cap?

Today LIVN has the market capitalization of 3.44B USD.